Skip to main content
MetaVia Inc. logo

MetaVia Inc. — Investor Relations & Filings

Ticker · MTVA ISIN · US64132R1077 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2016-06-13 Regulatory Filings
Country US United States of America
Listing US MTVA

About MetaVia Inc.

https://metaviatx.com/

MetaVia Inc. is a clinical-stage biotechnology company focused on developing novel pharmaceuticals for cardiometabolic diseases. The company's pipeline is centered on innovative treatments for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, DA-1726, is a dual oxyntomodulin (OXM) analog agonist that functions on both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR), under development for obesity. Another key asset is Vanoglipel, a G-Protein-Coupled Receptor 119 (GPR119) agonist being developed for MASH.

Recent filings

Filing Released Lang Actions
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to Form S-1 Registration Statement filed with the SEC, dated June 13, 2016, for Gemphire Therapeutics Inc. It includes a preliminary prospectus for an initial public offering (IPO) of common stock. The text references the Securities Act of 1933, registration fees, underwriting details, and the offering process. This type of filing is a registration statement used to register securities for public sale, which is distinct from annual reports, earnings releases, or other financial reports. The document is not a report of financial results or management discussion but a regulatory filing related to capital raising and securities registration. Therefore, the appropriate classification is Regulatory Filings (RNS).
2016-06-13 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter from legal counsel responding to a comment from the SEC staff regarding a Registration Statement on Form S-1 filed by Gemphire Therapeutics Inc. The letter discusses details about the company's potential Series B financing and its impact on stock valuation used in the registration statement. The document references the Form S-1 registration statement and addresses SEC comments but does not contain financial statements or detailed financial data itself. It is a regulatory correspondence related to a registration filing, not a financial report or earnings release. The document length is 5643 characters, which is relatively short and consistent with a regulatory filing or comment response letter. Therefore, this document fits best under Regulatory Filings (RNS), as it is a response to SEC comments on a registration statement and does not constitute the registration statement itself or a financial report.
2016-05-03 English
Regulatory Filings 2016
Regulatory Filings
2016-05-02 English
Regulatory Filings 2016
Regulatory Filings
2016-04-27 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a detailed letter from a company's legal counsel to the SEC staff regarding a Registration Statement on Form S-1 for an IPO. It discusses confidential treatment requests, stock option valuations, and the estimated offering price for the IPO. The content is focused on regulatory correspondence related to the IPO registration process, including valuation methodologies and stock compensation accounting. It is not a financial report, earnings release, or management discussion, but rather a regulatory filing responding to SEC comments on the Form S-1 registration statement. The document is lengthy (15,000 characters) and contains substantive content related to the registration process, not merely an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a regulatory correspondence document that does not fit into other specific categories like Annual Report or Capital Update.
2016-04-22 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Gemphire Therapeutics Inc. It is a preliminary prospectus related to an initial public offering (IPO) of common stock. The text includes details about the offering, underwriting, risk factors, management discussion and analysis, financial statements, and other disclosures typical of an IPO registration statement. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, earnings release, or management report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is not merely an announcement or a certification, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2016-04-18 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.